Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) insider Shafique Virani sold 18,000 shares of the company’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $9.25, for a total value of $166,500.00. Following the sale, the insider now owns 140,351 shares of the company’s stock, valued at approximately $1,298,246.75. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Shafique Virani also recently made the following trade(s):
- On Wednesday, July 26th, Shafique Virani sold 20,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $14.41, for a total value of $288,200.00.
- On Monday, July 17th, Shafique Virani sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $11.72, for a total value of $351,600.00.
- On Thursday, June 1st, Shafique Virani sold 25,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.58, for a total value of $214,500.00.
Recursion Pharmaceuticals Stock Down 2.3 %
Recursion Pharmaceuticals stock opened at $8.58 on Friday. The business has a 50 day moving average price of $10.36 and a two-hundred day moving average price of $8.28. Recursion Pharmaceuticals, Inc. has a 12 month low of $4.54 and a 12 month high of $16.75.
Hedge Funds Weigh In On Recursion Pharmaceuticals
Analyst Upgrades and Downgrades
Several research firms recently weighed in on RXRX. Needham & Company LLC reissued a “buy” rating and set a $17.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday, August 9th. Morgan Stanley began coverage on Recursion Pharmaceuticals in a research report on Monday, May 22nd. They set an “equal weight” rating and a $8.00 price objective for the company. Finally, KeyCorp boosted their price objective on Recursion Pharmaceuticals from $12.00 to $15.00 in a research report on Thursday, July 13th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $11.40.
Check Out Our Latest Analysis on Recursion Pharmaceuticals
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers.
Read More
- Five stocks we like better than Recursion Pharmaceuticals
- Crypto vs Stocks: How to Choose Your Investments
- MarketBeat Week in Review – 8/14 – 8/18
- What is the Euro STOXX 50 Index?
- 8 Best Artificial Intelligence Stocks Under $10
- Where Do I Find 52-Week Highs and Lows?
- What Ross Stores Earnings Say About The Saver Shopping Economy
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
